Hepatitis C: Looking for an Effective Regimen for Genotype 3

Article

Hepatitis C genotype 3 can be hard to cure, but researchers presenting a study at the Liver Meeting (AASLD) in San Francisco, CA, said they have found a regimen that works.

Hepatitis C genotype 3 can be hard to cure, but researchers presenting a study at the Liver Meeting (AASLD) in San Francisco, CA, said they have found a regimen that works.

Vincent LeRoy, MD, of the Centre Hospitalier Universitaire de Grenoble, La Tronche France, and colleagues at other institutions reported on a trial known as ALLY-3+.

Fifty patients with HCV-GT-3 were treated and most had already had other treatments. The patients got daclatasvir (Daklinza/Bristol-Myers-Squibb) sofosbuvir (Sovaldi/Gilead) and ribavirin (Rebetol/Merck). One arm of the group got the combo for 12 weeks and showed SVR4 rate of 88%. A second group took the drugs for 16 weeks and their SVR4 rate was 96%.

There were no virologic breakthroughs.

In an abstract presented at the meeting, the team concluded that the combination therapy “Achieved high SVR4 rates” in patients with HCV GT3 with compensated advanced fibrosis or cirrhosis “and was generally safe and well tolerated.”

Recent Videos
How to Address Blistering Diseases, with Donna Culton, MD, PhD
Matthew Zirwas, MD: Discussing Upadacitinib, Other JAK Inhibitors for Atopic Dermatitis
Differentiating Between Different Types of Alopecia, with Jerry Shapiro, MD
Julie Harper, MD: Discussing Acne Treatment Updates, Unmet Needs Among Patients
Using Microbiomes to Diagnose Ventilator-Associated Pneumonia
Discussing Unmet Needs Among Patients in Dermatology, with Matthew Zirwas, MD
Review of Recent Advancements in Dermatology, with Matthew Zirwas, MD
Allison Moser, MSN, RN, FNP-BC | Credit: Allison Moser on LinkedIn
Raj Chovatiya, MD, PhD: Treating Hidradenitis Suppurativa with IL-17, JAK Inhibitors
Most Promising New Drugs for Hidradenitis Suppurativa, with Raj Chovatiya, MD, PhD
© 2024 MJH Life Sciences

All rights reserved.